Aurobindo Pharma Limited has announced an upcoming investor group plant visit arranged by Investec, scheduled for January 13, 2026. The pharmaceutical company informed both the National Stock Exchange of India Limited and BSE Limited about this investor engagement through a regulatory filing dated January 8, 2026.

Visit Details and Schedule

The investor group plant visit will be conducted as an in-person meeting at the company's manufacturing facilities in Vizag and Kakinada. The comprehensive facility tour is scheduled to run from 09:00 AM to 05:00 PM IST, providing investors with an extended opportunity to examine the company's operations.

Regulatory Compliance and Information Sharing

Aurobindo Pharma has explicitly stated that no unpublished price sensitive information (UPSI) is intended to be discussed during the interactions with investors. This disclosure ensures compliance with regulatory requirements and maintains transparency in investor communications.

The company has also noted that the schedule of the plant visit remains subject to potential changes. Any modifications may occur due to exigencies on the part of either the investor group or the company itself.

Corporate Communication

The announcement was made through official communication to both major Indian stock exchanges, where Aurobindo Pharma Limited trades under the symbol AUROPHARMA on NSE and company code 524804 on BSE. The filing was digitally signed by B. Adi Reddy, Company Secretary, ensuring proper authorization and documentation of the investor engagement activity.

This plant visit represents part of Aurobindo Pharma's ongoing investor relations activities, providing institutional investors with direct access to the company's manufacturing operations and facilities across its key production locations in Andhra Pradesh.

Aurobindo Pharma Limited's wholly-owned subsidiary, Auro Pharma Limited, completed the acquisition of Khandelwal Laboratories Private Limited's branded non-oncology prescription formulations business on January 1 through a Business Transfer Agreement. The transaction, valued at ₹3,250 crores in cash consideration, was executed on a going concern basis and became effective from the same date.

Acquisition Structure and Terms

The deal involves the acquisition of Khandelwal's complete non-oncology prescription formulations business as a going concern, including inventory, intellectual property, employees, and contracts through a slump sale arrangement. The transaction does not involve acquisition of any shares or control of Khandelwal Laboratories itself.

Business Portfolio and Operations

The acquired business portfolio comprises 23 brands marketed across 67 SKUs and includes 9 pipeline products. The major therapeutic areas focus on anti-infective and pain management segments. The business operates with approximately 470 field staff and maintains a distribution network of over 1,600 stockists along with related infrastructure.

Financial Performance

Khandelwal Laboratories' non-oncology business, which has been operating since 1973-74, recorded a turnover of ₹1,135.30 crores with an EBITDA of ₹289.90 crores in FY2024-25. The business has demonstrated consistent performance over recent years.

Strategic Impact and Market Response

The acquisition is expected to strengthen Auro Pharma's presence in the domestic pharmaceutical market and complement its existing product portfolio in pain management and anti-infective segments. Management indicated that the deal will enhance the company's growth prospects and provide a wider range of prescription offerings to the domestic market.

Shares of Aurobindo Pharma ended higher by 1.18% at ₹1,197.00 following the announcement. The transaction required no governmental or regulatory approvals and does not constitute a related party transaction, with the promoter group having no interest in the acquired business.